DVA
DaVita Inc
7월 27일 2:38 PM ET (한국 7/28 03:38)
$235.44
+1.17 ▲ +0.50%
다비타(DVA) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
시가총액
$15.1B
미드캡
P/E
22.6
적정 수준
배당수익률
0.71%
52주 위치
97%
저점 +133% · 고점 -2%
애널리스트
보유
B-
Fundamental health
vs. Medical Care Facilities
수익성 Top 32%
성장 Top 49%
밸류에이션 Top 55%
재무 안정 Top 44%
💰 Is this stock pricier than usual right now?
Compared to this company's own recent 5년 (not other companies).
Very cheap
Cheap
Typical
Pricey
🔥 Very pricey
Simply put — what you pay today to own $1 of this company's yearly earnings is 14원. Over the past 5년, it usually traded around 10원. Earnings have also shrunk, which lifts the multiple — one of the priciest stretches of the past 5년.
Pricy doesn't mean bad — it means expectations are already baked in.
| Index | S&P 500 | P/E | 22.6 | EPS (ttm) | 10.42 | Insider Own | 2.07% | Shs Outstand | 66.2M | Perf Week | -0.65% |
| Market Cap | 15.12B | Forward P/E | 13.58 | EPS next Y | 16.48% | Insider Trans | -69.67% | Shs Float | 62.9M | Perf Month | 10.51% |
| Enterprise Value | 29.39B | PEG | 0.64 | EPS next Q | 3.88 | Inst Own | 96.4% | Short Float | 7.22% | Perf Quarter | 51.87% |
| Income | 0.76B | P/S | 1.09 | EPS this Y | 38.03% | Inst Trans | -3.83% | Short Ratio | 5.21 | Perf Half Y | 115.66% |
| Sales | 13.84B | P/B | - | EPS next 5Y | 21.14% | ROA | 4.37% | Short Interest | 4.54M | Perf YTD | 107.24% |
| Book/sh | -11.41 | P/C | 20.19 | EPS past 3/5Y | 18.56% 8.29% | ROE | 635.3% | 52W High | -1.75% ($239.64) | Perf Year | 62.63% |
| Cash/sh | 11.66 | P/FCF | 10.12 | Sales past 3/5Y | 5.53% 3.39% | ROIC | 6.35% | 52W Low | 133.11% ($101.00) | Perf 3Y | 130.6% |
| Dividend Est. | $1.67 (0.71%) | EV/EBITDA | 10.62 | EPS Y/Y TTM | 2.79% | Gross Margin | 27.27% | Volatility(W/M) | 2.22% 2.73% | Perf 5Y | 95.21% |
| Dividend TTM | - | EV/Sales | 2.12 | Sales Y/Y TTM | 6.68% | Oper. Margin | 14.82% | ATR (14) | 6.11 | Perf 10Y | 202.19% |
| Dividend Ex-Date | - | Quick Ratio | 1.37 | EPS Q/Q | 43.08% | Profit Margin | 5.47% | RSI (14) | 64.31 | Recom | 2.89 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.42 | Sales Q/Q | 5.96% | SMA20 | 1.73% ($231.44) | Beta | 0.88 | Target Price | $217.33 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/4 | SMA50 | 10.72% ($212.64) | Rel Volume | 0.61 | Prev Close | $234.27 |
| Employees | 78000 | LT Debt/Eq | - | EPS/Sales Surpr. | 23.18% 1.76% | SMA200 | 53.05% ($153.83) | Avg Volume(3M) | 0.87M | Price | $235.44 |
| IPO | 1995/10/31 | Option/Short | Yes/Yes | Trades | 9345 | Volume | 535,271 | Change | 0.5% |
Quarterly earnings trend SEC filings · USD
24.6
24.9
24.12*
25.3
25.6
25.9
25.12*
26.3
Revenue Net income 최근 분기: 매출 $3.4B (YoY +6%) · 순이익 $198M (YoY +21%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red
DaVita Inc (DVA) Investment Analysis
What kind of company is DaVita Inc?
다비타(DVA) 성장주
Healthcare · Medical Care Facilities
#730 by Market Cap — Mid-Cap
A leading U.S. provider of dialysis services, specializing in kidney care. The company operates a nationwide network of hemodialysis centers for patients with chronic kidney failure and offers related treatments and medical services, making it one of America's premier dialysis service companies.
Learn more about DaVita Inc →Market Cap
$15.1B
Approx. KRW 20.7 trillion
⚖️ 5% of Samsung Electronics
Market Cap Rank730
Employees78,000people
IPO1995/10/31
Current Price$235.44 ≈ 322,553원
Key Events
⏰ Upcoming events
🔔 Earnings release D-8
8월 4일 (화) · 장 마감 후
예상 EPS $3.88
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 5일 (화) · 장 마감 후 EPS +23.2% 매출 +1.8%
🔔 Earnings release 2026년 2월 2일 (월) · 장 마감 후 EPS +4.9% 매출 +3.2%
Is it profitable?
Financial health solid
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
14.8%
✓ 우수
Net Margin
Share of revenue left after taxes and interest are paid
5.5%
✓ 양호
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
27.3%
✓ 양호
ROE
Annual return earned on shareholders' equity (15%+ is strong)
635.3%
✓ 우수
ROA
Annual earnings relative to total company assets
4.4%
✓ 평균
ROIC
Return generated per dollar invested in the business
6.3%
✓ 평균
Financial health — Debt & liquidity burden
Current Ratio
Liquid assets available to cover liabilities due within a year
1.42
✓ 양호
Quick Ratio
Liquid assets excluding inventory, available for immediate use
1.37
✓ 양호
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).
What's the outlook?
Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$217.33
현재가 대비 -7.7%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
13.58배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
PEG (성장 반영 밸류)
0.64
저평가
💡 PEG < 1 — 성장 대비 저렴
내년 EPS 예상 성장률
+16.5%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+21.1%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.
Did earnings meet expectations?
High Earnings Reliability
Beat estimates in 2 of the last 2 quarters
2
예상 상회
0
예상 부합
0
예상 하회
100%
상회 비율
+14.8%
평균 서프라이즈
2026.05.05
상회
실적 $2.87 · 예상 $2.33 +23.2%
2026.02.02
상회
실적 $3.40 · 예상 $3.19 +6.5%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.
Is it growing?
Strong Growth
Above the industry average, both historically and going forward
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+38.0%
우수
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+16.5%
양호
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+21.1%
우수
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+18.6%
양호
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+8.3%
평균
Past 5-Year Revenue
How much revenue grew over the past 5 years
+3.4%
매우 부진
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+6.0%
부진
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →
Has the stock risen over the long term?
Slightly outperformed the market over 5 years (+27%p)
DVA +95.2% · S&P 500 +68.0%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
+27.3%p
ahead of the market
vs Health Care (XLV)
+71.6%p
well ahead of the sector average
1-year basis
vs S&P 500
+46.2%p
well ahead of the market
vs Health Care (XLV)
+42.9%p
well ahead of the sector average
Current position within 52-week range
Low (-133.1%p) High (-1.8%p)
Current price is 133.1% above the 52-week low and 1.8% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-7.8%
Annualized volatility
41.6%
Technical Indicators
Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series
Price · Bollinger Bands · Ichimoku Cloud
- close
- BB Upper
- BB Mid
- BB Lower
- Tenkan
- Kijun
- Cloud (SpanA/B)
Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →
Current diagnosis · 2026-07-24
Uptrend zone
Current price $235.44 above the midline ($231.45). Normal upward flow. Above the Ichimoku cloud (bullish).
MACD (12 · 26 · 9) Expand ▼
An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →
Current diagnosis · 2026-07-24
Neutral zone — weak trend
MACD 7.067 · Signal 8.246 · Hist -1.180. Weak directional bias.
RSI(14) · Stochastics %K(14) Expand ▼
RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →
Current diagnosis · 2026-07-24
Bullish zone
RSI 64.3 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 72.5.
※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.
Is it attractive at this price?
Cheaper than peers in its industry
Cheap on Vs. Earnings·Vs. Cash Flow, In line with peers on Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
Vs. Earnings Cheap
Vs. Sales Mid-range
Vs. Cash Flow Cheap
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
22.60x
✓ Fair
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
13.58x
✓ Cheap
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
1.09x
✓ Fair
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
10.62x
✓ Cheap
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
10.12x
✓ Cheap
Analyst target price (reference)
$217.33 vs. current price -7.7%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Medical Care Facilities
Who owns it?
Ownership backdrop is unfavorable
Insider net selling -69.7% · Institutional net selling -3.8% · Short interest moderate 7.2% · Short interest fell -2.4%p over the last 90 days
📈 Recent trading flow (6 months)
🧑💼 Insiders (executives & directors)
-69.7%
Insiders large net selling
🏦 Institutions (funds & investors)
-3.8%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 96.4%
Institution-led, stable structure
🧑💼 Insiders 2.1%
Typical level
👤 Retail investors (estimated) 1.5%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
7.2%
Moderate
Past 90 days 📉 -2.4%p decrease
Short interest days to cover
5.2 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 66.2M주
Float (tradable shares) 62.9M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.
ETFs holding DVA
ETFs with the highest weightings · 10 total shown
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.
How much does it pay in dividends?
배당 지급 — 연 0.71%
배당보다 주가 성장에 가까운 비중
Dividend Yield
0.71%
Industry average 1.25%
Dividend Per Share
$1.67
Annualized
Payout Ratio
0%
Share of net income paid as dividends
5-Year Growth
-
Annualized dividend growth
💰 내가 100만원 투자한다면
연간 배당금 (세후) 6,029원
5년 누적 (세후) 3.0만원
* 환율 1,370원, 세금 15% 반영. 5년 누적은 배당 성장률 연 0% 가정.
Compare Industry Peers
💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
| Stock | Market Cap | PER | PBR | ROE | Dividend Yield | Change |
|---|---|---|---|---|---|---|
| DVA This Stock | $15.1B | 22.6 ▲ | - | 635.3% ▲ | 0.71% ▼ | +0.5% |
LLY | $1.13T | 43.0 ▼ | 36.2 ▼ | 107.64% ▲ | 0.58% ▼ | +0.9% |
JNJ | $634.1B | 30.5 ▼ | 7.5 ▼ | 25.74% ▲ | 2.04% ▲ | +1.6% |
ABBV | $458.2B | 127.9 ▼ | - | 15221.82% ▲ | 2.65% ▲ | +0.9% |
UNH | $382.1B | 27.1 ▼ | 3.9 ▼ | 12.49% ▲ | 2.15% ▲ | -0.7% |
MRK | $323.7B | 36.9 ▼ | 7.1 ▼ | 18.97% ▲ | 2.49% ▲ | +0.5% |
| Sector Avg | - | 25.8 | 2.7 | -48.83% | 1.25% | - |
FAQ
What kind of company is 다비타(DVA)?
다비타(DVA) belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is the market cap of DVA?
The market cap of DVA is approximately $15.1B, ranking 730 within its sector.
Does DVA pay dividends?
DVA has a dividend yield of approximately 0.71%, with an annual dividend of $1.67.
What is the P/E ratio of DVA?
DVA has a P/E ratio of approximately 22.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for DVA?
DVA has recorded a 52-week high of $239.64 and a low of $101.00.
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.